Table II. Relative risk of each tumor subgroup and corresponding positive predictive value (PPV).
| Relative risk | ||||||
|---|---|---|---|---|---|---|
| ≤ 1 | > 1 | > 2 | > 3 | > 4 | ||
| Borderline | Absolute predicted risk | ≤ 6.3 | > 6.3 | > 12.6 | > 18.9 | > 25.2 |
| Observed PPV (%) | 2.0 | 18.4 | 23.9 | 26.0 | 29.7 | |
| Stage I cancer | Absolute predicted risk | ≤ 7.4 | > 7.4 | > 14.8 | > 22.2 | > 29.6 |
| Observed PPV (%) | 2.2 | 16.5 | 21.2 | 26.6 | 30.7 | |
| Stage II-IV cancer | Absolute predicted risk | ≤ 14.1 | > 14.1 | > 28.2 | > 42.3 | > 56.4 |
| Observed PPV (%) | 1.4 | 56.5 | 66.2 | 71.3 | 75.8 | |
| Secondary | Absolute predicted risk | ≤ 4.0 | > 4.0 | > 8.0 | > 12.0 | > 16.0 |
| metastatic cancer | Observed PPV (%) | 1.0 | 13.5 | 18.4 | 26.4 | 31.6 |
Relative risk: rate of change of the absolute predicted risk versus the baseline risk.
Observed PPV: the observed positive predictive value, i.e. the percentage of patients with a given outcome among those with a given relative risk for that outcome as observed in the sample of 5909 patients on which the final ADNEX coefficients were obtained. Note that this is an observed percentage that is unadjusted for clustering by center.